RE:RE:RE:RE:Revised Communication StrategyIt doesn't matter how/ when I define trial success- it matters when Baxter does.
As with most deals, the payout gets larger when the risk gets smaller/ eliminated.
I don't think it worth debating how other Biotechs are valued. We have a rocky trial road going back to 2010 Euphrates. We are in a "prove it" position before we would see the type of investor support as the Biotech you're comping.
That said, I believe that Baxter has already accesed the data. I believe the Jan 3rd meeting was to approve material changes to the partnership, and I believe since seeing the data Baxter has been activly involved in the 3.3X enrollment increase.
I believe we see an announcement from Baxter next week, I believe they will sweeten/ add to the 2.5m interim payment (considerably) and formally put their resouces into expiditing the trial.
let's see.